Fujifilm building $37m facility to support liposome drugs

By Dan Stanton contact

- Last updated on GMT


Related tags: Pharmacology, Pancreatic cancer

Toyama Chemical’s facility will support trials of lipsome drugs produced using technologies cultured through Fujifilm’s photographic film business.

The 4bn yen ($37m) facility will be built at a site in Toyama, japan run by Toyama Chemicals, a subsidiary of Fujifilm Corporation.

“The first purpose [of the plant] is the manufacturing of [our] own liposome drugs, including FF-10832 which will start clinical trial in the US this year,”​ Fujifilm spokesperson Kana Matsumoto told this publication.

Liposomes, or artificially constructed vesicles, are made from the same organic phospholipids that make up cell and bio membranes and can be designed to deliver active pharmaceutical ingredients (APIs) to specific areas.

Toyama’s FF-10832 consists of an anti-cancer drug Gemzar (gemcitabine), developed by Eli Lilly for the treatment of pancreatic cancer, formulated with liposomes with a uniform size of approximately 80nm.

But “Fujifilm will also collaborate with other companies for offering the liposome technology,”​ Matsumoto told us. “Fujifilm has advanced liposome technology, cultivated through photographic film business, and the production facility will be designed and developed by Fujifilm.”

She added the facility will make liposome drugs in compliance with international GMP standards, and will use Fujifilm’s Information and communication Technologies (ICT), including “centralised management of various data such as production process, quality evaluation and operation data.”

Construction of the new facility will begin in September, and operations are expected to begin in February 2020.

Related news

Related products

show more

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...


Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers